Clinical and Translational Research
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. May 15, 2024; 16(5): 1965-1994
Published online May 15, 2024. doi: 10.4251/wjgo.v16.i5.1965
To explore the mechanism of Yigong San anti-gastric cancer and immune regulation
Dou-Dou Lu, Ling Yuan, Zhao-Zhao Wang, Jian-Jun Zhao, Yu-Hua Du, Na Ning, Guo-Qing Chen, Shi-Cong Huang, Yi Yang, Zhe Zhang, Yi Nan
Dou-Dou Lu, School of Clinical Medicine, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Ling Yuan, Jian-Jun Zhao, Yu-Hua Du, Na Ning, Guo-Qing Chen, Shi-Cong Huang, Yi Yang, College of Pharmacy, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Zhao-Zhao Wang, Traditional Chinese Medicine College, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Zhe Zhang, Department of Chinese Medical Gastrointestinal, China-Japan Friendship Hospital, Beijing 100029, China
Yi Nan, Key Laboratory of Ningxia Minority Medicine Modernization Ministry of Education, Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China
Author contributions: Lu DD performed the research and wrote the paper; Yuan L, Zhang Z and Nan Y designed the research; Zhao JJ, Du YH and Ning N contributed new analytic tools; Wang ZZ, Chen GQ, Huang SC and Yang Y analyzed the data.
Supported by Ningxia Key Research and Development Program, No. 2023BEG02015; Ningxia Science and Technology Benefiting People Program, No. 2022CMG03064; Ningxia Natural Science Foundation, No. 2022AAC02039; and National Natural Science Foundation of China, No. 82260879 and No. 82374261.
Institutional review board statement: No animal experiments or human clinical trials are involved in this manuscript.
Informed consent statement: No clinical trials are involved in this manuscript.
Conflict-of-interest statement: All authors declare no financial or commercial conflict of interest for this manuscript.
Data sharing statement: All data generated or analyzed during this study are included in this paper, and further inquiries can be directed to the corresponding author (E-mail: 20080011@nxmu.edu.cn).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yi Nan, PhD, Professor, Key Laboratory of Ningxia Minority Medicine Modernization Ministry of Education, Ningxia Medical University, No. 1160 Shengli Street, Yinchuan 750004, Ningxia Hui Autonomous Region, China. 20080011@nxmu.edu.cn
Received: December 20, 2023
Peer-review started: December 20, 2023
First decision: January 10, 2024
Revised: January 21, 2024
Accepted: February 20, 2024
Article in press: February 20, 2024
Published online: May 15, 2024
Processing time: 141 Days and 1.5 Hours
Core Tip

Core Tip: Gastric cancer seriously endangers human life and quality of life. Traditional Chinese medicine has rich experience in treating tumors, and Yigong San (YGS) is a representative prescription that can treat a variety of digestive system diseases, but there is no study on the anti-gastric cancer effect of YGS. In this study, we used network pharmacology and bioinformatics methods to analyze the anti-gastric cancer mechanism of YGS, and to provide basis for the clinical treatment of gastric cancer.